In other words, for medium-sized tumors (100 to 400 mm3), given the same irradiation dose, CD47-KO is more effective in reducing the tumor than SIRPα-KO and anti-SIRPα, which in turn is more effective than anti-CD47. Here, SIRPA is linked to neoplasm.